Table 10: Key drivers of cationic emulsion technology Novasorb.

(i) Solubilization of large doses of lipophilic drugs and/or large molecules
(ii) Better penetration through membranes resulting in enhanced bioavailability
(iii) Potential for drug controlled release
(iv) Stable and can be sterilized
(v) Addition of effective novel routes of administration to existing marketed drugs
(vi) Expanding markets and indications
(vii) Extending product life cycles
(viii) Generating new opportunities
(ix) Inexpensive to manufacture